U.S., June 24 -- ClinicalTrials.gov registry received information related to the study (NCT07032311) titled 'Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk' on June 19.
Brief Summary: This clinical trial aims to find out if a digital behavioral program, delivered through the SIPPA digital therapeutics app, can help improve blood sugar control and lower the risk of liver fibrosis in adults with type 2 diabetes who are at low to moderate risk for liver disease.
Main Research Question:
Can adding the SIPPA behavioral program to standard diabetes care lower HbA1c (a marker of blood sugar control) more than standard care alone?
Study Design:
The study has two groups (called "arms") for comparison:
Arm 1: Control Group...